date,title,source
Nov-05-18,ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions,GlobeNewswire
Nov-12-18,GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions,GlobeNewswire
Nov-14-18,ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update,GlobeNewswire
Dec-20-18,ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial,GlobeNewswire
Dec-26-18,"ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling",Simply Wall St.
